BioTime Management to Present at Rodman & Renshaw 17th Annual Global Investment Conference
August 28 2015 - 8:30AM
Business Wire
BioTime, Inc. (NYSE MKT:BTX) announced today that BioTime
management will present at the Rodman & Renshaw 17th Annual
Investment Conference in New York City from 3:00 to 3:25 p.m. EDT
on Thursday, September 10, 2015. Investors will receive an update
on BioTime and its subsidiaries.
The investor presentation will also be available for a live
webcast by clicking on the following link:
http://www.wsw.com/webcast/rrshq25/btx. The webcast replay will
remain available for 90 days following the presentation.
Additionally, if you are an institutional investor, management
will be available for one-on-one meetings with attendees of the
conference. Investors are encouraged to contact their Rodman &
Renshaw representative or Investor Contact: EVC Group, Inc.,
Michael Polyviou.
About BioTime
BioTime, Inc., a pioneer in regenerative medicine, is a
clinical-stage biotechnology company. BioTime and its subsidiaries
are leveraging their industry-leading experience in pluripotent
stem cell technology and a broad intellectual property portfolio to
facilitate the development and use of cell-based therapies and gene
marker-based molecular diagnostics for major diseases and
degenerative conditions for which there presently are no cures. The
lead clinical programs of BioTime and its subsidiaries include
OpRegen®, currently in a Phase I/IIa trial for the treatment of the
dry form of age-related macular degeneration; AST-OPC1, currently
in a Phase I/IIa trial for spinal cord injuries; Renevia™,
currently in a pivotal trial in Europe as an injectable matrix for
the engraftment of transplanted cells to treat HIV-related
lipoatrophy; and cancer diagnostics that are nearing completion of
initial clinical studies for the detection of lung, breast and
bladder cancers. AST-VAC2, a cancer vaccine, is in the pre-clinical
trial stage.
BioTime’s family of companies include the publicly traded
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), developing
pluripotent stem cell-based therapies in neurology and oncology,
including AST-OPC1 and AST-VAC2; Cell Cure Neurosciences Ltd.,
developing stem cell-based therapies for retinal and neurological
disorders, including OpRegen® for dry AMD; OncoCyte Corporation,
developing non-invasive cancer diagnostics; LifeMap Sciences, Inc.,
developing and marketing an integrated online database resource for
biomedical and stem cell research; LifeMap Solutions, Inc., a
subsidiary of LifeMap Sciences, developing mobile health (mHealth)
products; ES Cell International Pte Ltd, which has developed
cGMP-compliant human embryonic stem cell lines that are being
marketed by BioTime for research purposes under the ESI BIO
branding program; OrthoCyte Corporation, developing therapies to
treat orthopedic disorders, diseases, and injuries; and ReCyte
Therapeutics, Inc., developing therapies to treat a variety of
cardiovascular and related ischemic disorders.
BioTime common stock is traded on the NYSE MKT under the symbol
BTX. For more information, please visit www.biotimeinc.com or
connect with the company on Twitter, LinkedIn, Facebook, YouTube,
and Google+.
Forward-Looking Statements
Statements pertaining to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for BioTime and its
subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to
statements that contain words such as “will,” “believes,” “plans,”
“anticipates,” “expects,” “estimates”) should also be considered to
be forward-looking statements. Forward-looking statements involve
risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the business of BioTime and
its subsidiaries, particularly those mentioned in the cautionary
statements found in BioTime’s Securities and Exchange Commission
filings. BioTime disclaims any intent or obligation to update these
forward-looking statements.
To receive ongoing BioTime corporate communications, please
click on the following link to join our email alert list:
http://news.biotimeinc.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150828005104/en/
BioTime, Inc.Dan L. Lawrence, 510-521-3390 ext.
349dlawrence@biotimemail.comorInvestor Contact:EVC Group,
Inc.Michael Polyviou, 646-445-4800mpolyviou@evcgroup.comorMedia
Contact:Gotham Communications, LLCBill Douglass,
646-504-0890bill@gothamcomm.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2023 to Apr 2024